세계의 주사용 약물전달 시장 : 제품별, 제형 포장별, 치료 용도별, 사용 패턴별, 투여 부위별, 최종사용자별, 지역별 - 예측(-2030년)

The injectable drug delivery devices market is projected to reach USD 373.7 billion by 2030 from USD 256.3 billion in 2025, at a CAGR of 7.8% during the forecast period. The injectable drug delivery formulations market is projected to reach USD 661.1 billion by 2030 from USD 434.0 billion in 2025, at a CAGR of 8.8% during the forecast period.

The injectable drug delivery market is experiencing rapid transformation due to the increasing demand for patient-centric, targeted, and minimally invasive treatment solutions. A significant trend in this market is the shift toward self-injection technologies, which include autoinjectors, pen injectors, and wearable injectors. These advancements enhance patient compliance and facilitate at-home care, which is especially important for managing chronic conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis.

Technological advancements are increasingly shaping the market. Smart injectors equipped with connectivity features, dose tracking, and reminder systems are becoming more popular, reflecting the broader trend toward digital healthcare. Furthermore, the integration of microneedles and needle-free injectors is helping to reduce the pain and anxiety often associated with traditional syringes, particularly for pediatric and geriatric populations.

The pharmaceutical industry increasingly focuses on long-acting formulations, biologics, and biosimilars, requiring precise delivery systems. This trend is fostering closer collaboration between drug developers and device manufacturers. Additionally, regulatory bodies are updating their frameworks to better support combination products, which is helping to accelerate product approvals.

"By device, the self-injection devices segment is projected to grow at the highest CAGR during the forecast period."

From 2025 to 2030, the self-injection devices segment is expected to grow at the highest rate within the injectable drug delivery market. This growth is driven by a global shift toward decentralized care, an increase in the prevalence of chronic diseases, and a growing emphasis on patient autonomy. Self-injection devices, which include autoinjectors, pen injectors, and wearable injectors, provide convenience and precision while reducing the need for clinical settings. This makes them particularly suitable for long-term therapies.

In the US and Canada, growth is driven by a high adoption rate of biologics for treating autoimmune and metabolic disorders, along with favorable reimbursement policies and the integration of digital technology in healthcare. Demand has increased significantly in Europe, particularly Germany, France, and the UK, due to the expanding geriatric population and well-structured chronic disease management programs. In the Asia Pacific region, countries such as Japan, China, and India are experiencing rapid growth due to improved healthcare access, increased patient awareness, and a rise in the availability of biosimilars.

Technological trends such as smart connectivity features, dose memory, and pain-reduction technologies make devices more appealing. The COVID-19 pandemic has also accelerated the adoption of self-care, as patients tend to avoid hospitals and prefer administering treatments at home. Collaborations between pharmaceutical companies and device manufacturers are increasing, allowing for customized solutions for injectable therapies. Overall, the rapid growth of this segment reflects a strong combination of clinical needs, patient preferences, and technological advancements.

"By formulation packaging, the ampoules segment accounted for the largest market share in 2024."

The ampoules segment was the leading contributor to market share within the injectable drug delivery market in 2024. Ampoules are the fastest-growing packaging segment in this market, driven by their superior sterility, affordability, and adaptability to a wide range of drug formulations. Typically made of glass or plastic, ampoules are ideal for preserving single-dose injectable solutions without the risk of contamination, making them highly preferred in acute care and hospital settings.

In developing economies like India, Brazil, and Vietnam, the cost-effectiveness of ampoules encourages their widespread use in government vaccination and immunization programs. Additionally, their compatibility with various biologics and small-molecule drugs further facilitates adoption across therapeutic areas such as oncology, anti-infectives, and hormonal therapies.

"The Asia Pacific (APAC) region is expected to witness the highest growth rate during the forecast period."

The Asia Pacific region is becoming the fastest-growing area in the injectable drug delivery market, driven by a combination of demographic, economic, and healthcare factors. The increasing prevalence of chronic diseases, particularly diabetes and cancer, in large countries like China and India, is creating a greater demand for advanced injectable therapies. Additionally, as access to biologics expands, there is an increased need for user-friendly devices, such as autoinjectors and pen injectors.

In China, supportive government policies, increasing investment in research and development, and a thriving biotechnology sector are driving the adoption of innovative drug delivery systems. Meanwhile, India, benefiting from a growing generics market, is also seeing significant growth in self-injection devices and biosimilars. Additionally, Southeast Asian countries like Vietnam and Thailand are enhancing their healthcare infrastructure and improving access to specialty care, which is boosting regional demand.

Urbanization, increasing disposable incomes, and a growing aging population contribute to the trend as patients and providers seek convenient, home-based treatment options. Additionally, regional manufacturing capabilities and cost-effective production attract partnerships from global pharmaceutical and device firms.

Breakdown of supply-side primary interviews: * By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%) * By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%) * By Region: North America (40%), Europe (25%), APAC (20%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews: * By Company Type: Hospitals (60%), Ambulatory Surgical Centers (25%), and Home Care Settings (15%) * By Designation: Directors (35%), Vice Presidents (27%), Managers (22%), and Other Designations (16%) * By Region: North America (40%), Europe (25%), APAC (20%), Latin America (10%), and the Middle East & Africa (5%)

Research Coverage

This report studies the injectable drug delivery market based on product, therapeutic application, formulation, packaging, usage pattern, site of administration, end user, and region. The report also studies factors affecting market growth (drivers, restraints, opportunities, and challenges). It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to six main regions and respective countries.

Reasons to Buy the Report

The report can assist both established companies and new or smaller firms understand the market trends, which will help them capture a larger market share. Firms that purchase the report can utilize one or more of the five strategies mentioned below.

This report provides insights into the following points:

• Analysis of key drivers (increasing chronic diseases, increasing biologics, and technological advancements), restraints (infections associated with needle-stick injuries), challenges (other methods of injectable drug delivery available in the market), and opportunities (increasing demand for generic medicines and biosimilars) influencing the growth of injectable drug delivery market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the injectable drug delivery market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of injectable drug delivery procedures across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the injectable drug delivery market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the injectable drug delivery market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS SEGMENTATION
  • 1.3.2 REGIONAL SEGMENTATION
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 INCLUSIONS AND EXCLUSIONS
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Breakdown of primaries
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH
  • 2.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
  • 2.2.3 APPROACH 3: TOP-DOWN APPROACH
  • 2.2.4 APPROACH 4: BOTTOM-UP APPROACH
  • 2.2.5 APPROACH 4: PRIMARY INTERVIEWS
  • 2.2.6 APPROACH 5: DEMAND-SIDE APPROACH
  • 2.2.7 APPROACH 6: VOLUME DATA ANALYSIS
• 2.3 DATA TRIANGULATION AND MARKET BREAKDOWN
• 2.4 MARKET SHARE ASSESSMENT
• 2.5 RESEARCH ASSUMPTIONS
  • 2.5.1 STUDY ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 INJECTABLE DRUG DELIVERY MARKET OVERVIEW
• 4.2 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET OVERVIEW
• 4.3 INJECTABLE DRUG DELIVERY MARKET: REGIONAL MIX
• 4.4 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
• 4.5 INJECTABLE DRUG DELIVERY MARKET: DEVELOPING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 MARKET DYNAMICS
  • 5.1.1 DRIVERS
    • 5.1.1.1 Growing demand for self-injection devices
    • 5.1.1.2 Advancements in drug delivery technologies
    • 5.1.1.3 Rising prevalence of chronic diseases
    • 5.1.1.4 Growing adoption of biologics and biosimilars
  • 5.1.2 RESTRAINTS
    • 5.1.2.1 Infections associated with needlestick injuries
    • 5.1.2.2 Stringent government regulations
  • 5.1.3 OPPORTUNITIES
    • 5.1.3.1 Development of novel drug delivery systems
    • 5.1.3.2 Growing preference for home-based care devices
    • 5.1.3.3 Growth opportunities in emerging economies
  • 5.1.4 CHALLENGES
    • 5.1.4.1 Alternative methods of drug delivery
    • 5.1.4.2 Complexities in developing wearable drug delivery systems
• 5.2 INDUSTRY TRENDS
  • 5.2.1 REUSABLE DRUG DELIVERY DEVICES
  • 5.2.2 PREFILLED BIOLOGICS
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
    • 5.4.1.1 Average selling price trend of key players, by device type
    • 5.4.1.2 Average selling price trend of key players, by pen injectors
  • 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
    • 5.4.2.1 Average selling price trend of pen injectors, by region
    • 5.4.2.2 Average selling price trend of needle-free injectors, by region
    • 5.4.2.3 Average selling price trend of autoinjectors, by region
    • 5.4.2.4 Average selling price trend of wearable injectors, by region
• 5.5 VALUE CHAIN ANALYSIS
  • 5.5.1 RESEARCH & PRODUCT DEVELOPMENT
  • 5.5.2 RAW MATERIAL PROCUREMENT
  • 5.5.3 MANUFACTURING
  • 5.5.4 MARKETING, SALES & DISTRIBUTION, AND AFTER-SALES SERVICES
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Autoinjectors and smart injection devices
    • 5.9.1.2 Needle-free injection systems and microneedle patches
    • 5.9.1.3 Wearable injectors for high-volume delivery
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Nanotechnology
    • 5.9.2.2 Biodegradable polymers
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Artificial intelligence and digital therapeutics
    • 5.9.3.2 Alternative routes of administration
• 5.10 PATENT ANALYSIS
  • 5.10.1 PATENT PUBLICATION TRENDS FOR INJECTABLE DRUG DELIVERY
  • 5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 TRADE DATA FOR HS CODE 901890
    • 5.11.1.1 Import data
    • 5.11.1.2 Export data
  • 5.11.2 TRADE DATA FOR HS CODE 90183100
    • 5.11.2.1 Import data
    • 5.11.2.2 Export data
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 CASE STUDY ANALYSIS
• 5.14 REGULATORY LANDSCAPE
  • 5.14.1 REGULATORY ANALYSIS
  • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.15 PORTER'S FIVE FORCES ANALYSIS
  • 5.15.1 BARGAINING POWER OF SUPPLIERS
  • 5.15.2 BARGAINING POWER OF BUYERS
  • 5.15.3 THREAT OF NEW ENTRANTS
  • 5.15.4 THREAT OF SUBSTITUTES
  • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS
  • 5.16.2 BUYING CRITERIA
    • 5.16.2.1 Buying criteria for injectable drug delivery devices
    • 5.16.2.2 Buying criteria for injectable drug delivery devices with formulations
• 5.17 PIPELINE ANALYSIS
• 5.18 REIMBURSEMENT ANALYSIS
• 5.19 UNMET NEEDS/END-USER EXPECTATIONS
• 5.20 IMPACT OF AI/GEN AI IN INJECTABLE DRUG DELIVERY MARKET
  • 5.20.1 INTRODUCTION
  • 5.20.2 MARKET POTENTIAL OF AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM
  • 5.20.3 AI USE CASES
  • 5.20.4 KEY COMPANIES IMPLEMENTING AI IN INJECTABLE DRUG DELIVERY DEVICES
  • 5.20.5 FUTURE OF GEN AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM
• 5.21 IMPACT OF 2025 US TARIFF
  • 5.21.1 INTRODUCTION
  • 5.21.2 KEY TARIFF RATES
  • 5.21.3 PRICE IMPACT ANALYSIS
  • 5.21.4 IMPACT ON COUNTRY/REGION
    • 5.21.4.1 North America
    • 5.21.4.2 Asia Pacific
    • 5.21.4.3 Europe
    • 5.21.4.4 Latin America
  • 5.21.5 IMPACT ON END-USE INDUSTRIES

6 INJECTABLE DRUG DELIVERY, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 DEVICES
  • 6.2.1 CONVENTIONAL INJECTION DEVICES
    • 6.2.1.1 By material
      • 6.2.1.1.1 Glass injectable devices
        • 6.2.1.1.1.1 Light protection, temperature resistance, and impermeability properties to drive market
      • 6.2.1.1.2 Plastic injectable devices
        • 6.2.1.1.2.1 Rapid increase in demand for syringes to aid growth
    • 6.2.1.2 By product
      • 6.2.1.2.1 Fillable syringes
        • 6.2.1.2.1.1 Ease of use and variable dosing formulations to boost market
      • 6.2.1.2.2 Prefilled syringes
        • 6.2.1.2.2.1 Minimal drug waste and low weight & space requirements to propel market
    • 6.2.1.3 By usability
      • 6.2.1.3.1 Reusable injection devices
        • 6.2.1.3.1.1 Cost-effective nature to contribute to growth
      • 6.2.1.3.2 Disposable injection devices
        • 6.2.1.3.2.1 Growing preference for ready-to-use devices to drive market
  • 6.2.2 SELF-INJECTION DEVICES
    • 6.2.2.1 Needle-free injectors
      • 6.2.2.1.1 By product
        • 6.2.2.1.1.1 Fillable needle-free injectors
        • 6.2.2.1.1.2 Prefilled needle-free injectors
      • 6.2.2.1.2 By technology
        • 6.2.2.1.2.1 Jet-based needle-free injectors
        • 6.2.2.1.2.2 Spring-based needle-free injectors
        • 6.2.2.1.2.3 Laser-powered needle-free injectors
        • 6.2.2.1.2.4 Vibration-based needle-free injectors
      • 6.2.2.1.3 By usability
        • 6.2.2.1.3.1 Reusable needle-free injectors
        • 6.2.2.1.3.2 Disposable needle-free injectors
    • 6.2.2.2 Autoinjectors
      • 6.2.2.2.1 By product
        • 6.2.2.2.1.1 Fillable autoinjectors
        • 6.2.2.2.1.2 Prefilled autoinjectors
      • 6.2.2.2.2 By technology
        • 6.2.2.2.2.1 Automated autoinjectors
        • 6.2.2.2.2.2 Manual autoinjectors
      • 6.2.2.2.3 By design
        • 6.2.2.2.3.1 Standardized autoinjectors
        • 6.2.2.2.3.2 Customized autoinjectors
      • 6.2.2.2.4 By usability
        • 6.2.2.2.4.1 Reusable autoinjectors
        • 6.2.2.2.4.2 Disposable autoinjectors
    • 6.2.2.3 Pen injectors
      • 6.2.2.3.1 By product
        • 6.2.2.3.1.1 Single-chambered pen injectors
        • 6.2.2.3.1.2 Double-chambered pen injectors.
      • 6.2.2.3.2 By design
        • 6.2.2.3.2.1 Standard pen injectors
        • 6.2.2.3.2.2 Customized pen injectors
      • 6.2.2.3.3 By usability
        • 6.2.2.3.3.1 Reusable pen injectors
        • 6.2.2.3.3.2 Disposable pen injectors
    • 6.2.2.4 Wearable injectors
      • 6.2.2.4.1 Increasing need for safe and convenient injections to accelerate growth
    • 6.2.2.5 Other self-injection devices
• 6.3 FORMULATIONS
  • 6.3.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
    • 6.3.1.1 Solutions
      • 6.3.1.1.1 High stability and sterility benefits to intensify growth
    • 6.3.1.2 Reconstituted/lyophilized formulations
      • 6.3.1.2.1 Higher suitability for parenteral administration to aid growth
    • 6.3.1.3 Suspensions
      • 6.3.1.3.1 Innovations in injectable suspensions for stable and sustained delivery to aid growth
    • 6.3.1.4 Emulsions
      • 6.3.1.4.1 Advancements in injectable emulsions for controlled and sustained drug delivery to drive market
  • 6.3.2 NOVEL DRUG DELIVERY FORMULATIONS
    • 6.3.2.1 Colloidal dispersions
      • 6.3.2.1.1 Niosomes
        • 6.3.2.1.1.1 Low toxicity and economical features to speed up growth.
      • 6.3.2.1.2 Liposomes
        • 6.3.2.1.2.1 Flexible, biocompatible, and fully biodegradable properties to boost market
      • 6.3.2.1.3 Polymeric/mixed micelles
        • 6.3.2.1.3.1 Ability to deliver hydrophobic drugs with slower dissolution rates to boost market
      • 6.3.2.1.4 Nanoparticles
        • 6.3.2.1.4.1 Solid-lipid nanoparticles
        • 6.3.2.1.4.2 Nanosuspensions
        • 6.3.2.1.4.3 Nanoemulsions
    • 6.3.2.2 Microparticles
      • 6.3.2.2.1 Microspheres
        • 6.3.2.2.1.1 Growing focus of major pharmaceutical companies on microsphere drug delivery to drive market
      • 6.3.2.2.2 Microcapsules
        • 6.3.2.2.2.1 Higher biocompatibility properties to augment growth
  • 6.3.3 LONG-ACTING INJECTABLE FORMULATIONS
    • 6.3.3.1 Decreased side effects and overall medical cost reduction to advance growth

7 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING

• 7.1 INTRODUCTION
• 7.2 AMPOULES
  • 7.2.1 EASE OF TRANSPORTATION AND LOW MANUFACTURING COST TO AID GROWTH
• 7.3 VIALS
  • 7.3.1 NEED FOR SECURE, DEPENDABLE, AND COST-EFFECTIVE CONTAINERS TO ENCOURAGE GROWTH
• 7.4 CARTRIDGES
  • 7.4.1 INCREASING FOCUS ON DOSE ACCURACY AND PATIENT CONVENIENCE TO FACILITATE GROWTH
• 7.5 BOTTLES
  • 7.5.1 RISING FOCUS ON SAFE STORAGE OF SOLUTIONS AND EMULSIONS TO FOSTER GROWTH

8 INJECTABLE DRUG DELIVERY, BY THERAPEUTIC APPLICATION

• 8.1 INTRODUCTION
• 8.2 AUTOIMMUNE DISEASES
  • 8.2.1 RHEUMATOID ARTHRITIS
    • 8.2.1.1 Increased focus on early-stage diagnosis and treatment to amplify growth
  • 8.2.2 MULTIPLE SCLEROSIS
    • 8.2.2.1 Increasing target patient pool to contribute to growth
  • 8.2.3 CROHN'S DISEASE
    • 8.2.3.1 Rising use of liposomes to aid growth
  • 8.2.4 PSORIASIS
    • 8.2.4.1 Lifestyle changes and high disease prevalence to support growth
  • 8.2.5 OTHER AUTOIMMUNE DISEASES
• 8.3 HORMONAL DISORDERS
  • 8.3.1 DIABETES
    • 8.3.1.1 Growing preference for self-injection devices over traditional syringes to drive market
  • 8.3.2 REPRODUCTIVE HEALTH DISEASES
    • 8.3.2.1 Lack of healthcare facilities and hygiene practices to aid growth
  • 8.3.3 ANTITHROMBOTIC/THROMBOLYTIC THERAPY
    • 8.3.3.1 High efficacy and safety of heparin for antithrombotic therapy to aid growth
  • 8.3.4 OSTEOPOROSIS
    • 8.3.4.1 Increasing number of women with calcium and vitamin D deficiencies to foster growth
  • 8.3.5 GROWTH HORMONE DEFICIENCY
    • 8.3.5.1 Increased need for daily injections of recombinant human growth hormones to fuel market
• 8.4 OBESITY
  • 8.4.1 CHANGING SEDENTARY LIFESTYLE AND CONSUMPTION OF OVER-PROCESSED FOODS TO AID GROWTH
• 8.5 CANCER
  • 8.5.1 INCREASING LAUNCHES OF NEW VACCINES AND TARGETED THERAPIES TO BOLSTER GROWTH
• 8.6 INFECTIOUS DISEASES
  • 8.6.1 GROWING ADVANCEMENTS IN INJECTABLE THERAPIES TO DRIVE MARKET
• 8.7 ORPHAN DISEASES
  • 8.7.1 FAVORABLE GOVERNMENT INITIATIVES TO AUGMENT GROWTH
• 8.8 OTHER THERAPEUTIC APPLICATIONS
  • 8.8.1 PAIN MANAGEMENT
    • 8.8.1.1 Growing focus on treating chronic pain to drive market
  • 8.8.2 ALLERGIES
    • 8.8.2.1 Increasing prevalence of asthma and eczema to promote growth
  • 8.8.3 AESTHETIC TREATMENTS
    • 8.8.3.1 Growing popularity of aesthetic procedures to propel market
  • 8.8.4 HEPATITIS C
    • 8.8.4.1 Need to curb virus spread due to needle reshare to sustain growth
  • 8.8.5 HEMOPHILIA
    • 8.8.5.1 Increasing need for preventive treatment plans to assist growth

9 INJECTABLE DRUG DELIVERY, BY USAGE PATTERN

• 9.1 INTRODUCTION
• 9.2 CURATIVE CARE
  • 9.2.1 RISE IN INFECTIOUS DISEASES TO ACCELERATE GROWTH
• 9.3 IMMUNIZATION
  • 9.3.1 GROWING DEMAND FOR VACCINES FROM HEALTHCARE ORGANIZATIONS TO DRIVE MARKET
• 9.4 OTHER USAGE PATTERNS

10 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION

• 10.1 INTRODUCTION
• 10.2 DERMAL-BASED ADMINISTRATION
  • 10.2.1 RAPID AND EFFECTIVE METHOD WITH LOW PAIN TO AMPLIFY GROWTH
• 10.3 CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION
  • 10.3.1 HIGH PREFERENCE FOR EMERGENCY CARE TO SUPPORT GROWTH
• 10.4 ORGAN-BASED ADMINISTRATION
  • 10.4.1 GROWING UTILIZATION OF INTRAVITREAL AND INTRA-OCULAR INJECTIONS IN COMPLEX PROCEDURES TO BOOST MARKET
• 10.5 CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION
  • 10.5.1 INCREASING FOCUS ON PAIN MANAGEMENT TO PROMOTE GROWTH

11 INJECTABLE DRUG DELIVERY MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 HOSPITALS & CLINICS
  • 11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
• 11.3 HOME CARE SETTINGS
  • 11.3.1 GROWING TREND OF SELF-ADMINISTRATION TO PROPEL MARKET
• 11.4 LONG-TERM CARE SETTINGS
  • 11.4.1 BOOMING ELDERLY POPULATION AND BURDEN OF CHRONIC DISEASES TO EXPEDITE GROWTH
• 11.5 NURSING HOMES
  • 11.5.1 GLOBAL SHIFT TOWARD AGED POPULATION TO STIMULATE GROWTH
• 11.6 OTHER END USERS

12 INJECTABLE DRUG DELIVERY MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 Increasing prevalence of chronic diseases to expedite growth
  • 12.2.3 CANADA
    • 12.2.3.1 Growing preference for self-injection devices to drive market
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 High healthcare spending to propel growth
  • 12.3.3 UK
    • 12.3.3.1 Rising cases of obesity and diabetes to promote growth
  • 12.3.4 FRANCE
    • 12.3.4.1 Favorable health insurance system to accelerate growth
  • 12.3.5 SPAIN
    • 12.3.5.1 Favorable healthcare regulations support growth
  • 12.3.6 ITALY
    • 12.3.6.1 Regional variation in terms of coverage and benefits to hinder growth
  • 12.3.7 NETHERLANDS
    • 12.3.7.1 Growing focus on enhanced patient care to drive market
  • 12.3.8 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Large patient population and healthcare infrastructure improvements to augment growth
  • 12.4.3 JAPAN
    • 12.4.3.1 Supportive reimbursement policies and universal healthcare coverage to aid growth
  • 12.4.4 INDIA
    • 12.4.4.1 Rising diabetes and cardiovascular disease burden to propel market
  • 12.4.5 AUSTRALIA
    • 12.4.5.1 Increased patient volume to contribute to growth
  • 12.4.6 SOUTH KOREA
    • 12.4.6.1 Rising incidence of obesity and hypertension to amplify growth
  • 12.4.7 THAILAND
    • 12.4.7.1 Expanding self-administration options to support growth
  • 12.4.8 VIETNAM
    • 12.4.8.1 Rising investments and regulatory reforms to support market growth
  • 12.4.9 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Surge in obesity issues to stimulate growth
  • 12.5.3 MEXICO
    • 12.5.3.1 Increasing incidence of chronic diseases to drive market
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Saudi Arabia
      • 12.6.2.1.1 Healthcare reforms to contribute to growth
    • 12.6.2.2 United Arab Emirates (UAE)
      • 12.6.2.2.1 Growing infrastructure investments to drive market
    • 12.6.2.3 Rest of GCC Countries
  • 12.6.3 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 OVERVIEW
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 13.3 REVENUE ANALYSIS, 2020-2024
  • 13.3.1 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
  • 13.3.2 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
• 13.4 MARKET SHARE ANALYSIS, 2024
  • 13.4.1 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
  • 13.4.2 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
• 13.5 BRAND/PRODUCT COMPARISON
• 13.6 R&D EXPENDITURE OF KEY PLAYERS
• 13.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.7.1 COMPANY VALUATION
  • 13.7.2 FINANCIAL METRICS
• 13.8 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • 13.8.1 STARS
  • 13.8.2 EMERGING LEADERS
  • 13.8.3 PERVASIVE PLAYERS
  • 13.8.4 PARTICIPANTS
  • 13.8.5 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY FOOTPRINT, 2024
    • 13.8.5.1 Company footprint
    • 13.8.5.2 Region footprint
    • 13.8.5.3 Product type footprint
    • 13.8.5.4 Usage pattern footprint
    • 13.8.5.5 Therapeutic application footprint
    • 13.8.5.6 Site of administration footprint
• 13.9 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • 13.9.1 PROGRESSIVE COMPANIES
  • 13.9.2 RESPONSIVE COMPANIES
  • 13.9.3 DYNAMIC COMPANIES
  • 13.9.4 STARTING BLOCKS
  • 13.9.5 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024
    • 13.9.5.1 Detailed list of key startups/SMEs
    • 13.9.5.2 Competitive benchmarking of startups/SMES
• 13.10 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • 13.10.1 STARS
  • 13.10.2 EMERGING LEADERS
  • 13.10.3 PERVASIVE PLAYERS
  • 13.10.4 PARTICIPANTS
  • 13.10.5 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY FOOTPRINT, 2024
    • 13.10.5.1 Company footprint
    • 13.10.5.2 Region footprint
    • 13.10.5.3 Product type footprint
    • 13.10.5.4 Formulation packaging type footprint
    • 13.10.5.5 Therapeutic application footprint
    • 13.10.5.6 Site of administration footprint
• 13.11 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • 13.11.1 PROGRESSIVE COMPANIES
  • 13.11.2 RESPONSIVE COMPANIES
  • 13.11.3 DYNAMIC COMPANIES
  • 13.11.4 STARTING BLOCKS
  • 13.11.5 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2024
    • 13.11.5.1 Detailed list of key startups/SMEs
    • 13.11.5.2 Competitive benchmarking of startups/SMEs
• 13.12 COMPETITIVE SCENARIO
  • 13.12.1 PRODUCT LAUNCHES AND APPROVALS
  • 13.12.2 DEALS
  • 13.12.3 EXPANSIONS

14 COMPANY PROFILES: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS

• 14.1 KEY PLAYERS
  • 14.1.1 CARDINAL HEALTH
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Right to win
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 BD
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Deals
      • 14.1.2.3.2 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Right to win
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 B. BRAUN SE
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 MnM view
      • 14.1.3.3.1 Right to win
      • 14.1.3.3.2 Strategic choices
      • 14.1.3.3.3 Weaknesses and competitive threats
  • 14.1.4 BAXTER
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches and approvals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Right to win
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 TERUMO CORPORATION
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches and approvals
      • 14.1.5.3.2 Expansions
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Right to win
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 PHILLIPS-MEDSIZE CORPORATION (MOLEX)
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches and approvals
      • 14.1.6.3.2 Deals
      • 14.1.6.3.3 Expansions
  • 14.1.7 NIPRO
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Expansions
  • 14.1.8 ICU MEDICAL, INC.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Deals
  • 14.1.9 WEST PHARMACEUTICAL SERVICES, INC.
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Deals
      • 14.1.9.3.2 Expansions
  • 14.1.10 GERRESHEIMER AG
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Product launches and approvals
      • 14.1.10.3.2 Deals
      • 14.1.10.3.3 Expansions
  • 14.1.11 STEVANATO
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Product launches and approvals
      • 14.1.11.3.2 Deals
      • 14.1.11.3.3 Expansions
  • 14.1.12 SCHOTT PHARMA
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Product launches and approvals
      • 14.1.12.3.2 Deals
      • 14.1.12.3.3 Expansions
  • 14.1.13 MEDMIX
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Product launches and approvals
      • 14.1.13.3.2 Deals
  • 14.1.14 SOLM
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products offered
  • 14.1.15 YPSOMED
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products offered
    • 14.1.15.3 Recent developments
      • 14.1.15.3.1 Deals
      • 14.1.15.3.2 Expansions
• 14.2 OTHER PLAYERS
  • 14.2.1 OWEN MUMFORD
  • 14.2.2 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.
  • 14.2.3 POLYMEDICURE
  • 14.2.4 UNION MEDICO INC.
  • 14.2.5 SHL MEDICAL
  • 14.2.6 ELCAM MEDICAL

15 COMPANY PROFILES: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS

• 15.1 KEY PLAYERS
  • 15.1.1 JOHNSON & JOHNSON SERVICES, INC.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches and approvals
      • 15.1.1.3.2 Deals
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Right to win
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses and competitive threats
  • 15.1.2 F. HOFFMANN-LA ROCHE LTD
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Product launches and approvals
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Right to win
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses and competitive threats
  • 15.1.3 PFIZER INC.
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product launches and approvals
      • 15.1.3.3.2 Deals
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Right to win
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses and competitive threats
  • 15.1.4 MERCK & CO., INC.
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Product launches and approvals
      • 15.1.4.3.2 Deals
      • 15.1.4.3.3 Expansions
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Right to win
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses and competitive threats
  • 15.1.5 NOVARTIS AG
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Product launches and approvals
      • 15.1.5.3.2 Deals
      • 15.1.5.3.3 Expansions
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Right to win
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses and competitive threats
  • 15.1.6 BAYER AG
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Product launches and approvals
      • 15.1.6.3.2 Expansions
  • 15.1.7 ASTRAZENECA
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Product launches and approvals
      • 15.1.7.3.2 Deals
      • 15.1.7.3.3 Expansions
  • 15.1.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Product launches and approvals
      • 15.1.8.3.2 Deals
      • 15.1.8.3.3 Expansions
  • 15.1.9 ELI LILLY AND COMPANY
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Product launches and approvals
      • 15.1.9.3.2 Expansions
  • 15.1.10 AMGEN INC.
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Product launches and approvals
      • 15.1.10.3.2 Deals
      • 15.1.10.3.3 Expansions
  • 15.1.11 NOVO NORDISK A/S
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Product launches and approvals
      • 15.1.11.3.2 Deals
      • 15.1.11.3.3 Expansions
  • 15.1.12 REGENERON PHARMACEUTICALS INC.
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products offered
      • 15.1.12.2.1 Product launches and approvals
      • 15.1.12.2.2 Deals
  • 15.1.13 FRESENIUS KABI AG
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products offered
    • 15.1.13.3 Recent developments
      • 15.1.13.3.1 Product launches and approvals
  • 15.1.14 UCB S.A.
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Product launches and approvals
  • 15.1.15 BIO-THERA SOLUTIONS, LTD.
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Product launches and approvals
• 15.2 OTHER PLAYERS
  • 15.2.1 SAGENT
  • 15.2.2 VALNEVA SE
  • 15.2.3 XERIS PHARMACEUTICALS, INC.
  • 15.2.4 PHARMAESSENTIA CORPORATION
  • 15.2.5 HERON THERAPEUTICS, INC.

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 RELATED REPORTS
• 16.4 AUTHOR DETAILS